Form 8-K - Current report:
SEC Accession No. 0001714899-25-000067
Filing Date
2025-02-27
Accepted
2025-02-27 16:12:41
Documents
16
Period of Report
2025-02-27
Items
Item 1.01: Entry into a Material Definitive Agreement
Item 1.02: Termination of a Material Definitive Agreement
Item 2.02: Results of Operations and Financial Condition
Item 9.01: Financial Statements and Exhibits

Document Format Files

Seq Description Document Type Size
1 8-K dnli-20250227.htm   iXBRL 8-K 38811
2 EX-1.1 exhibit11-sx3asr22725.htm EX-1.1 267920
3 EX-99.1 ex991pressreleaseq42024.htm EX-99.1 93835
7 denali_txlogox02.jpg GRAPHIC 604226
  Complete submission text file 0001714899-25-000067.txt   1416249

Data Files

Seq Description Document Type Size
4 XBRL TAXONOMY EXTENSION SCHEMA DOCUMENT dnli-20250227.xsd EX-101.SCH 1815
5 XBRL TAXONOMY EXTENSION LABEL LINKBASE DOCUMENT dnli-20250227_lab.xml EX-101.LAB 21629
6 XBRL TAXONOMY EXTENSION PRESENTATION LINKBASE DOCUMENT dnli-20250227_pre.xml EX-101.PRE 12530
18 EXTRACTED XBRL INSTANCE DOCUMENT dnli-20250227_htm.xml XML 2730
Mailing Address 161 OYSTER POINT BLVD. SOUTH SAN FRANCISCO CA 94080
Business Address 161 OYSTER POINT BLVD. SOUTH SAN FRANCISCO CA 94080 (650) 866-8547
Denali Therapeutics Inc. (Filer) CIK: 0001714899 (see all company filings)

EIN.: 463872213 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 8-K | Act: 34 | File No.: 001-38311 | Film No.: 25678895
SIC: 2836 Biological Products, (No Diagnostic Substances)
(CF Office: 03 Life Sciences)